Page 2290 - Hematology_ Basic Principles and Practice ( PDFDrive )

2033.e4 Part XII Hemostasis and Thrombosis

haemophilia-A and inhibitors: the results of an international survey. 152. Hay CR, Dimichele DM: The principal results of the International
Thromb Haemost 75:25–29, 1996. Immune Tolerance Study: a Randomized Dose Comparison. Blood
130. Kempton CL, Meeks SL: Towards optimal therapy for inhibitors in 119:1335, 2011.
Hemophilia. Hematology Am Soc Hematol Educ Program 2014:364, 153. Nakar C, Manco-Johnson MJ, Lail A, et al: Prompt immune tolerance
2014. induction at inhibitor diagnosis regardless of titre may increase overall
131. Tiede A, Friedrich U, Stenmo C, et al: Safety and pharmacokinet- success in haemophilia A complicated by inhibitors: experience of two
ics of subcutaneously administered recombinant activated factor VII US centres. Haemophilia 21:365, 2015.
(rFVIIa). J Thromb Haemost 9:1191–1199, 2011. 154. Hay CR, Ludlam CA, Colvin BT, et al: Factor VIII inhibitors in mild
132. Shima M, Hanabusa H, Taki M, et al: Factor VIII-mimetic function and moderate-severity haemophilia A. UK Haemophilia Centre Direc-
of humanized bispecific antibody in hemophilia A. N Engl J Med tors Organisation. Thromb Haemost 79:762–766, 1998.
373:2044–2053, 2016. 155. Kempton CL, Allen G, Hord J, et al: Eradication of factor VIII inhibi-
133. Brackmann HH, Gormsen J: Massive factor-VIII infusion in haemo- tors in patients with mild and moderate hemophilia A. Am J Hematol
philiac with factor-VIII inhibitor, high responder. Lancet 2:933, 1977. 87:933–936, 2012.
134. Brackmann HH, Oldenburg J, Schwaab R: Immune tolerance for the 156. Curtis J, Teo J, Schoemark R, et al: Use of Rituximab in patients with
treatment of factor VIII inhibitors—Twenty years’ “Bonn protocol. Vox congenital bleeding disorders and high-titre inhibitors. Blood 114:1359,
Sang 70:30, 1996. 2009.
135. Oldenburg J, Schwaab R, Brackmann HH: Induction of immune 157. Leissinger C, Josephson CD, Granger S, et al: Rituximab for treatment
tolerance in haemophilia A inhibitor patients by the “Bonn Protocol”: of inhibitors in haemophilia A. A Phase II study. Thromb Haemost
Predictive parameter for therapy duration and outcome. Vox Sang 112:445–458, 2014.
77:49, 1999. 158. Coppola A, Margaglione M, Santagostino E, et al: Factor VIII gene
136. Nilsson IM, Jonsson S, Sundqvist SB, et al: A procedure for removing (F8) mutations as predictors of outcome in immune tolerance induction
high titer antibodies by extracorporeal protein-A-sepharose adsorption of hemophilia A patients with high-responding inhibitors. J Thromb
in hemophilia: substitution therapy and surgery in a patient with Haemost 7:1809–1815, 2009.
hemophilia B and antibodies. Blood 58:38, 1981. 159. Stennicke HR, Kjalke M, Karpf DM, et al: A novel B-domain
137. Freiburghaus C, Berntorp E, Ekman M, et al: Tolerance induction O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and
using the Malmo treatment model 1982-1995. Haemophilia 5:32, prolonged effect in hemophilic mice models. Blood 121:2108–2116,
1999. 2013.
138. Berntorp E, Astermark J, Carlborg E: Immune tolerance induction and 160. De Groot AS, Moise L, McMurry JA, et al: Activation of natural
the treatment of hemophilia. Malmo protocol update. Haematologica regulatory T cells by IgG Fc-derived peptide “Tregitopes. Blood
85:48, 2000. 112:3303–3311, 2008.
139. Van Leeuwen EF, Mauser-Bunschoten EP, Van Dijken PJ, et al: Disap- 161. Briet E, Reisner HM, Roberts HR: Inhibitors in Christmas disease. Prog
pearance of factor VIII: C antibodies in patients with haemophilia A Clin Biol Res 150:123, 1984.
upon frequent administration of factor VIII in intermediate or low 162. Warrier I: Antibodies to factor IX. Haematologica 85:31, 2000.
dose. Br J Haematol 64:291, 1986. 163. Warrier I, Ewenstein BM, Koerper MA, et al: Factor IX inhibitors
140. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, et al: and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 19:23,
Low-dose immune tolerance induction in hemophilia A patients with 1997.
inhibitors. Blood 86:983, 1995. 164. Lillicrap D: The molecular basis of haemophilia B. Haemophilia 4:350,
141. Mariani G, Ghirardini A, Bellocco R: Immunetolerance in hemophilia- 1998.
principal results from the International Registry. Report of the factor 165. Hay CR, Baglin TP, Collins PW, et al: The diagnosis and management
VIII and IX Subcommittee. Thromb Haemost 72:155, 1994. of factor VIII and IX inhibitors: A guideline from the UK Haemophilia
142. Mariani G, Kroner B, on behalf of the Immune Tolerance Study Group: Centre Doctors’ Organization (UKHCDO). Br J Haematol 111:78,
Immune tolerance in hemophilia with factor VIII inhibitors: predictors 2000.
of success. Haematologica 86:1186, 2001. 166. Warrier I: Management of haemophilia B patients with inhibitors and
143. Mariani G, Siragusa S, Kroner B: Immune tolerance induction in anaphylaxis. Haemophilia 4:574, 1998.
hemophilia A: a review. Semin Thromb Hemost 29:69, 2003. 167. Shibata M, Shima M, Misu H, et al: Management of haemophilia
144. DiMichele DM, Kroner BL: Analysis of the North American Immune B inhibitor patients with anaphylactic reactions to FIX concentrates.
Tolerance Registry (NAITR) 1993-1997: Current practice implica- Haemophilia 9:269, 2003.
tions. ISTH Factor VIII/IX Subcommittee Members. Vox Sang 77:31, 168. Thorland EC, Drost JB, Lusher JM, et al: Anaphylactic response
1999. to factor IX replacement therapy in haemophilia B patients: Com-
145. DiMichele DM, Kroner BL: The North American Immune Tolerance plete gene deletions confer the highest risk. Haemophilia 5:101,
Registry: practices, Outcomes, Outcome Predictors. Thromb Haemost 1999.
87:52, 2002. 169. Recht M, Pollmann H, Tagliaferri A, et al: A retrospective study to
146. Lenk H: The German Registry of immune tolerance treatment in describe the incidence of moderate to severe allergic reactions to FIX
hemophilia—1999 update. Haematologica 85:45, 2000. in subjects with haemophilia B. Haemophilia 17:494, 2011.
147. Berntorp E: Variation in factor VIII inhibitor reactivity with differ- 170. Ewenstein BM, Takemoto C, Warrier I, et al: Nephrotic syndrome as
ent commercial factor VIII preparations: Is it of clinical importance? a complication of immune tolerance in hemophilia B. Blood 89:1115,
Haematologica 88:EREP03, 2003. 1997.
148. Ettingshausen CE, Kreuz W: Role of von Willebrand factor in immune 171. Tengborn L, Hansson S, Fasth A, et al: Anaphylactoid reactions and
tolerance induction. Blood Coagul Fibrinolysis 16:S27, 2005. nephrotic syndrome—A considerable risk during factor IX treatment in
149. Robertson JD, Higgins P, Price J, et al: Immune tolerance induction patients with haemophilia B and inhibitors: A report on the outcome
using a factor VIII/von Willebrand factor concentrate (BIOSTATE), in two brothers. Haemophilia 4:854, 1998.
with or without immunosuppression, in Australian paediatric severe 172. Bernstein J, Gupta N, Berkowitz R: Successful treatment of FIX
haemophilia A patients with high titre inhibitors: a multicentre, retro- complicated by nephrotic syndrome with Rituxan. Blood 110:Abstract
spective study. Thromb Res 134:1046–1051, 2014. 3971, 2007.
150. Escuriola Ettingshausen C, Kreuz W: A review of immune tolerance 173. Alexander S, Hopewell S, Hunter S, et al: Rituximab and desensitiza-
induction with Haemate P in haemophilia A. Haemophilia 20:333–339, tion for a patient with severe factor IX deficiency, inhibitors and history
2014. of anaphylaxis. J Pediatr Hematol Oncol 30:93, 2008.
151. Dimichele DM, Hay CR: The international immune tolerance study: a 174. Cross DC, Van Der Berg HM: Cyclosporin A can achieve immune
multicenter prospective randomized trial in progress. J Thromb Haemost tolerance in a patient with severe haemophilia B and refractory inhibi-
4:2271, 2006. tors. Haemophilia 13:111, 2007.